Webdisclosure.com

NANOHALE AG (FRA:FYB)

30/11/2023 07:30

EQS-News: Formycon and Fresenius Kabi announce File Acceptance for FYB202, a biosimilar candidate to Stelara® (ustekinumab), by the U.S. Food and Drug Administration

Voir tous les communiqués de Nanohale AG

NANOHALE AG (FRA:FYB)

27/11/2023 07:30

EQS-News: Formycon announces EMA submission for FYB203, a biosimilar candidate to Eylea® (Aflibercept)

Voir tous les communiqués de Nanohale AG

NANOHALE AG (FRA:FYB)

13/11/2023 07:30

EQS-News: Formycon publishes nine-month results for 2023

Voir tous les communiqués de Nanohale AG

NANOHALE AG (FRA:FYB)

10/11/2023 06:30

EQS-News: Formycon hosts conference call on nine-month figures 2023 and presents at further investor conferences

Voir tous les communiqués de Nanohale AG

NANOHALE AG (FRA:FYB)

10/10/2023 07:30

EQS-News: Formycon Ranibizumab Biosimilar FYB201/CIMERLI®1 achieved 25% market share2 in the United States

Voir tous les communiqués de Nanohale AG

NANOHALE AG (FRA:FYB)

29/09/2023 07:30

EQS-News: Formycon and Fresenius Kabi announce European Medicines Agency Submission Acceptance of the Marketing Authorization Application for FYB202, an Ustekinumab Biosimilar Candidate

Voir tous les communiqués de Nanohale AG

NANOHALE AG (FRA:FYB)

30/08/2023 07:30

EQS-News: Formycon reports successful first half of 2023

Voir tous les communiqués de Nanohale AG

NANOHALE AG (FRA:FYB)

29/08/2023 07:30

EQS-News: Formycon announces File Acceptance for FYB203, a biosimilar candidate to Eylea®1 (aflibercept), by the U.S. Food and Drug Administration (FDA)

Voir tous les communiqués de Nanohale AG

NANOHALE AG (FRA:FYB)

23/08/2023 07:30

EQS-News: Formycon hosts conference call on financial and earnings position for H1 2023

Voir tous les communiqués de Nanohale AG

NANOHALE AG (FRA:FYB)

21/08/2023 13:42

Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy

Voir tous les communiqués de Nanohale AG

1
2
3
4
5
6
7
8
9
10